Plasma TAFI Antigen Variations in Healthy Subjects

P. Chetaille; M. C. Alessi; D. Kouassi; P. E. Morange; I. Juhan-Vague

doi:10.1055/s-0037-1613941

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2000; 83(06): 902-905
DOI: 10.1055/s-0037-1613941

Commentary

Schattauer GmbH

Plasma TAFI Antigen Variations in Healthy Subjects

P. Chetaille

²From the Laboratory of Hematology, University of Medicine La Timone, Marseille, France

,

M. C. Alessi

²From the Laboratory of Hematology, University of Medicine La Timone, Marseille, France

,

D. Kouassi

¹Faculty of Pharmacy, Abidjan, Ivory Coast

,

P. E. Morange

²From the Laboratory of Hematology, University of Medicine La Timone, Marseille, France

,

I. Juhan-Vague

²From the Laboratory of Hematology, University of Medicine La Timone, Marseille, France

› Institutsangaben

Abstract

Summary

The Thrombin Activatable Fibrinolysis Inhibitor (TAFI) is a recently described inhibitor of fibrinolysis. The physiological variations of plasma TAFI antigen are not well known. We studied TAFI antigen values in healthy populations with a commercially available kit from Milan Analytica (Switzerland). Broad range of TAFI antigen values (from 41% to 259%) was found in a population of 249 healthy individuals. Gender as well as pregnancy did not influence mean values of TAFI antigen. There was a positive correlation between TAFI antigen and age in female (r = 0.28; p <0.05) but not in male populations. Mean TAFI antigen value of a black African male group [mean ± SD (range): 87 ± 23 (39-144%)] was significantly lower than the one of age matched Caucasian men [114 ± 34 (52-259%)] (p <0.0001). TAFI antigen values were very stable within individuals, they did not significantly vary on day time or at several months period.

Thus, in contrast to large inter-individual variations, TAFI antigen levels are quite stable within individuals.

Keywords

TAFI - carboxypeptidase B - physiological variations - healthy population

Volltext

Referenzen

References
1 Hendricks D, Scharpé S, van Sande M, Lommaert MP. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem 1989; 27: 277-85.
2 Campbell W, Okada H. An arginin specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem Biophys Res Commun 1989; 162: 933-9.
3 Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-8.
4 Bajzar L, Manuel R, Neisheim ME. Purification and characterization of TAFI, a thrombin activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14777-84.
5 Bajzar L, Morser J, Neisheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombinthrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
6 Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 14777-88.
7 Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-8.
8 Bajzar L, Neisheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 2093-100.
9 Wang M, Nagashima M, Morser J. Thrombin activable fibrinolysis inhibitor in rats, rabbits and dogs. Fibrinolysis & Proteolysis 1998; 12 (Suppl. 01) 12.
10 Von dem Borne PAK, Bajzar L, Meijers JCM, Neisheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a Thrombin-Activatable Fibrinolysis Inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99: 2323-7.
11 Broze Jr G, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and premature lysis of clots from hemophilic plasma. Blood 1996; 88: 3815-23.
12 Bajzar L, Kalafatis M, Simioni P, Tracy PB. An antifibrinolytic mechanism describing the prothrombotic effect associated with factor V Leiden. J Biol Chem 1996; 271: 22949-52.
13 Hudson I, De Bono DP. Levels of carboxypeptidase B (thrombin-activable fibrinolysis inhibitor: TAFIa) following thrombolysis with streptokinase. Fibrinolysis & Proteolysis 1998; 12 (Suppl. 01) 12.
14 Refino CJ, Schmitt D, Pater C, Eaton D, Bunting S. A carboxypeptidase inhibitor markedly improves the potency of tPA in vivo. Blood 1998; 92: 550a.
15 Neisheim ME. TAFI. Fibrinolysis and Proteolysis 1999; 13: 72-7.
16 Redlitz A, Nicolini FA, Malycky JL, Topol EJ, Plow EF. Inducible carboxypeptidase activity: a role in clot lysis in vivo. Circulation 1996; 93: 1328-30.
17 Mosnier LO, von der Borne PAK, Meijers JCM, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-35.
18 Juhan-Vague I, Alessi MC, Raccah D, Aillaud MF, Billerey M, Ansaldi J, Philip-Joet C, Vague P. Daytime fluctuations of Plasminogen Activator Inhibitor 1 (PAI-1) in populations with high PAI-1 levels. Thromb Haemost 1992; 67: 76-82.
19 Schatteman KA, Goossens FJ, Scharpé SS, Neels HM, Hendriks DF. Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma. Clin Chem 1999; 45: 807-13.